NEWS
Find a Professional: Explore Experts Across 197 Disciplines in 221 Countries!
Just Updated: Compare Your Institution (Live Data)
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025 (Updated Today)
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
Login
Register & Pricing
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
For Students
local_fire_department
Country Reports
person
Find a Professional
Victor Van De Wiele
University of Cambridge - Cambridge / United Kingdom
Law / Law and Legal Studies
AD Scientific Index ID: 5144027
Registration, Add Profile,
Premium Membership
Get Your Global Impact Certificate
University of Cambridge
Ranking &
Analysis
Job
Experiences
Education
Information
Published Books
Book Chapters
Articles
Presentations
Lessons
Projects
Co-Authors
Subject Leaders
Editorship, Referee &
Scientific Board
Patents /
Designs
Academic Grants
& Awards
Artistic
Activities
Certificate / Course
/ Trainings
Association &
Society Memberships
Contact, Office
& Social Media
person_outline
Victor Van De Wiele's MOST POPULAR ARTICLES
1-)
Assessment of variation in state regulation of generic drug and interchangeable biologic substitutions JAMA Internal Medicine 181 (1), 16-22, 2021
2-)
Barriers To US Biosimilar Market Growth: Lessons From Biosimilar Patent Litigation: Article examines barriers to US biosimilar market growth. Health Affairs 40 (8), 1198-1205, 2021
3-)
The characteristics of patents impacting availability of biosimilars Nature Biotechnology 40 (1), 22-25, 2022
4-)
Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases Journal of Law and the Biosciences 9 (1), lsac001, 2022
5-)
Frequency of approval and marketing of biosimilars with a skinny label and associated Medicare savings JAMA Internal Medicine 183 (1), 82-84, 2023
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept